Pacific Biosciences Of California (PACB) Receivables (2010 - 2026)

Pacific Biosciences Of California's Receivables history runs 17 years deep, the most recent figure standing at $29.4 million for Q1 2026.

• In Q1 2026, Receivables fell 7.25% year-over-year to $29.4 million; the TTM figure through Mar 2026 stood at $29.4 million (down 7.25% YoY), while the FY2025 annual figure was $35.4 million, up 28.79% from the prior year.
• Receivables was $29.4 million for Q1 2026 at Pacific Biosciences Of California, down from $35.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $36.6 million in Q4 2023 to a low of $18.8 million in Q4 2022.
• Historically, Receivables has averaged $29.2 million across 5 years, with a median of $29.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables jumped 115.81% in 2022, then slipped 24.83% in 2024.
• A 5-year view of Receivables shows it stood at $18.8 million in 2022, then surged by 94.91% to $36.6 million in 2023, then slipped by 24.83% to $27.5 million in 2024, then grew by 28.79% to $35.4 million in 2025, then declined by 17.2% to $29.4 million in 2026.
• The last three Receivables figures came in at $29.4 million (Q1 2026), $35.4 million (Q4 2025), and $30.6 million (Q3 2025), per Business Quant data.